Aerocrine AB Announces the Appointment of Scott Myers to the Position of President and Chief Executive Officer

Aerocrine AB (OMX Nordic Exchange: AERO) today announced that Scott Myers has been appointed as President and CEO of Aerocrine AB, effective as of today. This appointment is part of the company’s strategy to focus on the reimbursement and commercialization of its products in the U.S. and other key markets. Scott succeeds Paul de Potocki who has successfully led the development of Aerocrine since 2007.

Scott brings 20 years of experience in the pharmaceutical and health care consulting industries to the company. He joins Aerocrine from UCB, a €3.0 billion global biopharmaceutical company where most recently he held the position of VP, Head of European Mid-Markets. In this role, Scott had overall responsibility for a region with a €400 million turnover that covered 30 countries and employed over 600 people. Under Scott’s leadership, group operating profit increased significantly and he led the launches of several drugs, including Innovair for asthma.

"Aerocrine’s Board and management have worked purposefully to establish the company’s U.S. operations and commercial organization. The U.S. is the world’s largest market for Aerocrine’s products and we expect that market conditions in the U.S. will continue to develop favorably,” said Anders Williamsson, chairman of the Board. "Scott's appointment is a natural and important step in the company’s long term strategy and we are delighted to welcome Scott to Aerocrine.”

Prior to UCB, Scott held several senior positions at Johnson & Johnson including Senior Vice President and General Manager of McNeil Specialty Products. In that position, Scott led a group of over 700 people and had overall responsibility for the $800 million pharmaceutical portfolio.

"I am thrilled to join Aerocrine. With the recent release of the American Thoracic Society guideline that strongly recommends the use of FENO measurement to be included in the standard of care for asthma, our company is poised to provide our products for use in helping to manage this chronic disease. We will build on the strong foundations Aerocrine has achieved to date and widen reimbursement and patient access to NIOX MINO which addresses a real and unmet medical need in how asthma patients manage their condition”, said Scott Myers.

Mr. Williamsson continued, "Aerocrine has taken a completely new biomarker and method in one of the world’s most widespread diseases to the international markets. This is quite unique in the life science industry and I wish to thank Paul de Potocki for his vital role in this accomplishment. Aerocrine’s critical next steps are to achieve full reimbursement and drive uptake of NIOX MINO in the U.S. and other key markets. Scott brings valuable experience to help Aerocrine achieve these goals".

"Aerocrine has launched its products in over 40 countries and we have strong clinical acceptance as well as positive development of FENO reimbursement in the U.S. With unique products, a strong patent estate and an exciting program with Panasonic Healthcare in place to drive the next wave of innovative products and services, we have created a solid foundation for Aerocrine’s next stage of development. I look forward to supporting the company’s continued progress,”said Paul de Potocki.

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:55 a.m. on September 13, 2011.

This information was brought to you by Cision http://www.cisionwire.com